Our work philosophy for The SCN2A Foundation will be to work quickly, efficiently, strategically, collaboratively, and transparently.
PITTSBURGH (PRWEB) February 28, 2023
Marketing Leader Turned Rare Disease Researcher - Dad launches new rare disease foundation to focus on accelerating targeted research for the SCN2A disease & unite the data silos challenging progress.
“Since our son’s diagnosis 3 years ago and after almost losing him, we’ve been self-funding research and educating ourselves on this disease. I've been mulling over launching a research non-profit now for over 2 years, but didn’t want to throw my hat in the ring unless I knew we could be effective. Over the past year though, we’ve made significant strides and have partnered with many very talented individuals in both the research and development of precision medicine. Considering the prevalence of our disease, and where we’re at currently, I think it's time to start rallying troops to match up with the likes of Angelman Syndrome.” - stated Jason Curry, Co-Founder and Director of the SCN2A Foundation.
SCN2A is a gene that helps regulate the central nervous system. Malfunctions in this gene can cause complex and deadly symptoms relating to autism and epilepsy that are difficult to treat with general antiepileptic medications. The SCN2A Foundation will be dedicated and focused on accelerating targeted research and treatment for this disease through partnering with strategic partners, and using cutting edge technologies and processes.
“Our work philosophy for The SCN2A Foundation will be to work quickly, efficiently, strategically, collaboratively, and transparently. And we’ve built a small but mighty team of board members that include Ryan Quiel - with a background in growth marketing for NonProfits, Mathew Lawrence - with a background in clinical research and insurance, Shannon Curry - a registered nurse, and Dr. John Golden - an attorney and professor specializing in healthcare law.” stated Jason Curry.
About the SCN2A Foundation
Incorporated in 2023 - Our mission is to accelerate targeted research and treatment for the SCN2A through strategic, and cutting edge technologies, processes, and partnerships. For more information, visit https://www.scn2afoundation.org, or follow us on Twitter, Facebook, Instagram, or Linkedin.